Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)

• Type of Material: Article
• Authors: Paolo A Ascierto, Istituto Nazionale Tumor IRCCS “Fondazione G; Antonio Avallone, Istituto Nazionale Tumor IRCCS “Fondazione G; Carlo Bifulco, Providence Cancer Institute, Portland; Sergio Bracarda, Azienda Ospedaliera Santa Maria, Terni; Joshua D Brody, Icahn School of Medicine at Mount Sinai; Leisha A Emens, University of Pittsburgh; Robert L Ferris, University of Pittsburgh; Silvia C Formenti, Weill Cornell Medicine, New York; Omid Hamid, Cedars-Sinai Affiliate, Los Angeles; Douglas B Johnson, Vanderbilt University; Tomas Kirchhoff, New York University; Christopher A Klebanoff, Memorial Sloan Kettering Cancer Center, New York; Gregory B Lesinski, Emory University; Anne Monette, Jewish General Hospital, Montreal; Bart Neyns, University Hospital Brussel; Kunle Odunsi, University of Chicago; Chrystal M Paulos, Emory University; Daniel J Powell Jr, University of Pennsylvania; Katayoun Rezvani, University of Texas MD Anderson; Brahm H Segal, Roswell Park Comprehensive Cancer Center, Buffalo; Nathan Singh, Washington University; Ryan J Sullivan, Massachusetts General Hospital; Bernard A Fox, Providence Cancer Institute, Portland; Igor Puzanov, Roswell Park Comprehensive Cancer Center
• Language: English
• Date: 2023-07-20
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2023
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s12967-023-04329-7
• Title of Journal or Parent Work: JOURNAL OF TRANSLATIONAL MEDICINE
• Volume: 21
• Issue: 1
• Start Page: 488
• End Page: 488
• Grant/Funding Information: Funding:Not applicable.
• Keywords: PHASE-III; Science & Technology; OPEN-LABEL; Immunotherapy; CHEMOTHERAPY; T-CELLS; Vaccine; RECEPTOR; Combination therapy; Checkpoint inhibitors; Tumor microenvironment; CARCINOMA; CELL LUNG-CANCER; FOLLOW-UP; Medicine, Research & Experimental; Biomarkers; TUMOR; NIVOLUMAB; Life Sciences & Biomedicine; Research & Experimental Medicine
• Research Categories: Health Sciences, Pathology; Health Sciences, Oncology; Health Sciences, Immunology; Biology, Microbiology

Abstract

The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th–December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.